Healthcare / Diagnostics Company Valuation: EBITDA, Capacity and Growth Case Study
₹45.00 cr
FY26 diagnostics revenue18.00%
Normalized EBITDA margin₹86.60 cr
Concluded enterprise value₹1,772
Concluded equity value per share01. The Business Was More Than One EBITDA Multiple
The subject company operated four diagnostics centres across western India, supported by collection points and a B2B reference-testing network. It had been operating for seven years and had built a mix of routine pathology, preventive-health packages and higher-value specialty tests.
FY26 revenue was ₹45.00 crore, generated from approximately 8.00 lakh tests at an average realisation of ₹562.50 per test. Reported EBITDA was ₹7.65 crore, equal to 17.00% of revenue.
The company had incurred ₹0.45 crore of one-time launch and pre-opening costs for its proposed fifth centre. Adding these back produced ₹8.10 crore normalized EBITDA / 18.00% margin. PAT was approximately ₹3.90 crore, cash was ₹4.50 crore and debt was ₹2.50 crore.
Management planned to invest approximately ₹7.00 crore in the fifth centre and expand specialty-test capability. The valuation therefore had to distinguish mature-centre economics from expansion-centre ramp-up, while comparing the company with listed diagnostics businesses that were substantially larger and geographically more diversified.
“Diagnostics valuation is driven by more than EBITDA: centre maturity, test mix, average realisation, utilisation, collection reach and expansion capex determine how quickly accounting profit becomes free cash flow.”
02. Six Healthcare-Specific Risks Behind the Valuation
The company was profitable, but its value still depended on how much of that profitability came from mature centres and how much future value depended on successful expansion.
| Challenge Area | Description & Valuation Impact |
|---|---|
| Centre-Level CapacityUtilisation Risk | Mature centres operated at stronger utilisation than recently expanded units. Forecasting revenue only through a group-level CAGR would ignore physical capacity and ramp-up constraints. |
| Test Mix and RealisationRevenue Quality | Routine pathology carried lower average realisation than specialty tests and preventive packages. Revenue growth therefore had to separate volume growth from mix-driven pricing. |
| Doctor / Channel DependenceReferral Risk | B2B and doctor-referred business increased utilisation but could carry lower pricing and referral concentration. Direct-to-consumer home collection had higher marketing and logistics costs. |
| One-Time Expansion CostEBITDA Normalisation | ₹0.45 crore of pre-opening expenditure related to the fifth centre was not part of mature recurring operations and was therefore treated separately in sustainable EBITDA. |
| Capex and Ramp-UpFree-Cash-Flow Drag | The proposed fifth centre required approximately ₹7.00 crore capex before reaching full utilisation. EBITDA multiples alone would not capture the near-term cash investment required to create the new capacity. |
| Listed-Peer Scale GapMultiple Discount | Listed diagnostics peers had broader networks, stronger brands and geographic diversification. The selected trading multiple therefore required a material scale/geography discount before being applied to the regional company. |
03. Building Revenue by Centre, Then Valuing the Network
The DCF began with the operating units and expansion plan; the market approach then tested whether the resulting value was reasonable relative to listed diagnostics businesses.
Phase A: Reconstruct current revenue from test volume and realisation
Centre 1 generated ₹14.40 crore, Centre 2 ₹11.50 crore, Centre 3 ₹8.80 crore, Centre 4 ₹6.30 crore and the B2B/reference network ₹4.00 crore. Together they reconciled exactly to ₹45.00 crore FY26 revenue.
Phase B: Normalize EBITDA and centre economics
Reported EBITDA of ₹7.65 crore was increased by ₹0.45 crore one-time fifth-centre launch cost, giving ₹8.10 crore normalized EBITDA. Mature-centre margins were used to benchmark the expected margin path of new capacity.
Phase C: Forecast volumes, realisation and the fifth-centre ramp-up
Revenue was forecast at ₹52.00, ₹61.00, ₹70.00, ₹79.00 and ₹87.00 crore over Years 1–5. EBITDA margins expanded from 19.00% to 22.00% as the fifth centre scaled and specialty tests increased in the mix.
Phase D: Run the DCF after capex and working-capital needs
The model included the ₹7.00 crore expansion capex, maintenance capex, receivables and centre working capital. Using a 15.50% WACC and 5.00% terminal growth produced ₹86.00 crore enterprise value.
Phase E: Adjust listed-peer multiples for scale and geography
The selected listed-diagnostics peer set indicated materially higher trading multiples because of national networks and liquidity. After a scale/geography adjustment, a 10.80x EV/EBITDA multiple was selected. Applied to ₹8.10 crore normalized EBITDA, it produced ₹87.48 crore EV.
Phase F: Reconcile EV and derive equity value
DCF was weighted 60% and the market approach 40%: ₹86.00 × 60% + ₹87.48 × 40% = ₹86.59 crore, rounded to ₹86.60 crore EV. Adding ₹2.00 crore net cash produced ₹88.60 crore equity value. With 5,00,000 shares, the conclusion was approximately ₹1,772 per share.
6 diagnostics valuation components applied:
Centre-Level Revenue Model
Volumes × average realisation reconciled the ₹45.00 crore current revenue base.
Normalized EBITDA
₹0.45 crore of one-time launch costs were separated from mature operating profitability.
Expansion-Capex DCF
₹7.00 crore fifth-centre capex and ramp-up economics were incorporated directly into cash flow.
Listed-Peer Cross-Check
Peer multiples were adjusted for scale, liquidity, brand and geographic footprint.
Test-Mix Analysis
Routine, specialty and preventive-test mix informed average realisation and margin expansion.
EV-to-Equity Bridge
₹2.00 crore net cash increased ₹86.60 crore EV to ₹88.60 crore equity value.
FY26 centre / channel revenue build:
| Centre / Channel | Annual Test Volume | Average Realisation | Revenue |
|---|---|---|---|
| Centre 1 — Mature flagship | 2.40 lakh | ₹600 | ₹14.40 cr |
| Centre 2 — Mature urban | 2.00 lakh | ₹575 | ₹11.50 cr |
| Centre 3 — Growth centre | 1.60 lakh | ₹550 | ₹8.80 cr |
| Centre 4 — Newer satellite | 1.20 lakh | ₹525 | ₹6.30 cr |
| B2B / reference testing | 0.80 lakh | ₹500 | ₹4.00 cr |
| Total | 8.00 lakh | ₹562.50 weighted average | ₹45.00 cr |
Five-year operating model:
| Metric | FY27E | FY28E | FY29E | FY30E | FY31E |
|---|---|---|---|---|---|
| Revenue | ₹52.00 cr | ₹61.00 cr | ₹70.00 cr | ₹79.00 cr | ₹87.00 cr |
| EBITDA margin | 19.00% | 20.00% | 21.00% | 22.00% | 22.00% |
| EBITDA | ₹9.88 cr | ₹12.20 cr | ₹14.70 cr | ₹17.38 cr | ₹19.14 cr |
| Growth driver | Fifth-centre opening | Ramp-up | Specialty-test mix | Network maturity | Steady-state scale |
DCF vs listed-peer reconciliation:
| Method | Key Input | Indicated EV | Weight | Weighted EV |
|---|---|---|---|---|
| DCF | WACC 15.50%; TGR 5.00% | ₹86.00 cr | 60% | ₹51.60 cr |
| Listed-peer multiple | 10.80x × ₹8.10 cr normalized EBITDA | ₹87.48 cr | 40% | ₹34.99 cr |
| Concluded enterprise value | — | — | 100% | ₹86.59 cr ≈ ₹86.60 cr |
Valuation framework applied to a diagnostics business
Revenue should be capacity-linked: centre count, test volumes, utilisation, average realisation and test mix provide a more reliable forecast than applying one group-level CAGR without operating support.
Expansion capex belongs in DCF: a new centre can depress near-term cash flow before adding mature EBITDA. Applying a current EBITDA multiple without recognising the required capex can overstate value.
Peer multiples need scale adjustment: larger listed diagnostics businesses typically benefit from national brand recognition, broader collection networks, geographic diversification and liquidity. Those advantages should be reflected when selecting a multiple for a smaller regional company.
One-time launch cost can be normalized, but future expansion cannot be ignored: historical pre-opening cost may be non-recurring for current EBITDA, while the actual future capex and ramp-up cash flows still belong in the valuation forecast.
Purpose-specific requirements remain separate: if the valuation supports a transaction, preferential issue, tax, FEMA or accounting purpose, the relevant statutory framework should be assessed separately from the commercial business-value analysis.
04. Result: ₹86.60 Crore EV after Capacity and Scale Adjustments
The final valuation captured both the economics of the existing four-centre network and the cash investment needed to create the next phase of growth.
₹45.00 cr
FY26 diagnostics revenue18.00%
Normalized EBITDA margin₹86.60 cr
Concluded enterprise value₹1,772
Concluded equity value per share- Current revenue was independently rebuilt as 8.00 lakh tests × ₹562.50 weighted average realisation = ₹45.00 crore.
- Removing ₹0.45 crore one-time pre-opening cost increased EBITDA from ₹7.65 crore to ₹8.10 crore / 18.00%.
- The DCF produced ₹86.00 crore EV after explicitly funding the ₹7.00 crore fifth-centre expansion and its ramp-up period.
- A 10.80x scale-adjusted EV/EBITDA multiple produced ₹87.48 crore EV, providing a close independent market cross-check.
- The 60:40 reconciliation concluded ₹86.60 crore EV; adding ₹2.00 crore net cash produced ₹88.60 crore equity value and approximately ₹1,772 per share.
05. Five Lessons from a Healthcare / Diagnostics Valuation
Diagnostics valuations become more defensible when the revenue forecast can be traced to centres, tests, realisation and capex rather than only to historical EBITDA growth.
Build revenue from test volume and realisation
The ₹45.00 crore base was reconciled to 8.00 lakh tests and centre-level pricing. This made the growth forecast operationally challengeable rather than purely financial.
Separate mature centres from expansion centres
The fifth centre required ₹7.00 crore before it could contribute mature EBITDA. Treating every centre as immediately productive would overstate free cash flow.
Test mix can matter more than headline volume
Specialty tests and preventive packages supported higher realisation and margins than routine pathology. Volume growth without mix analysis can misstate revenue quality.
Do not copy listed-company multiples directly
National listed peers benefit from size, brand, geographic diversification and liquidity. A regional four-centre network warranted a meaningful scale adjustment before using their trading multiples.
Normalize historical launch costs but include future expansion cash
The ₹0.45 crore historic pre-opening cost was added back to normalized EBITDA, while the next ₹7.00 crore centre investment remained fully reflected in the DCF.
Why Choose Elite Valuation for Healthcare & Diagnostics Valuation Services
Elite Valuation supports diagnostics companies, hospitals, healthcare promoters, investors and transaction teams with sector-specific business Valuation and financial modelling.
For diagnostics assignments, the firm links centre-level volumes, average realisation, test mix, utilisation, capex, working capital and margin expansion to DCF and market-multiple conclusions instead of relying on one generic healthcare multiple.
Led by Sagar Shah (CA, CS, IBBI Registered Valuer), Elite Valuation can support fundraising, shareholder transactions, acquisitions, financial reporting and other purpose-specific healthcare valuation requirements.
Sagar Shah — CA | CS | IBBI Registered Valuer
Founder, Elite Valuation
Sagar Shah is the founder of Elite Valuation and a qualified Chartered Accountant, Company Secretary, and IBBI Registered Valuer with prior experience at Ernst & Young. He specialises in business Valuation, M&A advisory, ESOP Valuation, FEMA compliance, and regulatory Valuation across the Companies Act, SEBI, and RBI frameworks. Elite Valuation operates pan-India from Ahmedabad, advising companies of all stages and sizes.
